A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 6-mercaptopurine (6MP) in combination
with methotrexate (MTX) in patients with breast or ovarian cancer who are known to have a
BRCA (breast cancer gene) mutation.